entertainment -WSS

entertainment

author：leisure time 2025-10-01 02:27:31 - browse：5

Elf Bar disposable vape flavored vaping e-cigarette products are displayed in a convenience store. — The FDA is ramping up its efforts to force vape shops and other retailers to stop selling Elf Bar and Esco Bar products. PATRICK T. FALLON/AFP via Getty Images

WASHINGTON — The Food and Drug Administration is ramping up its efforts to force vape shops and other retailers to stop selling unauthorized disposable vape brands that are increasingly popular with young people.

The FDA recently issued 189 formal warning letters to shops selling two brands of vape products, Elf Bar and Esco Bars, the agency announced in a press release Thursday. The FDA has not authorized either brand, both of which are ubiquitous in gas stations and smoke shops around the country. They are therefore illegal to sell.

“This latest blitz should be a wake-up call for retailers of Elf Bar and Esco Bars products nationwide,” said Brian King, the head of the FDA’s tobacco center in a statement announcing the blitz.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： $1 billion proposal to grow Boston, Massachusetts biotech

explore

knowledge

WSS

Harvard's David Sinclair gets blowback over aging

Is there really a nursing shortage in the U.S.?

STAT Summit: How researchers deal with rejection

Roche drug slashes death risk in early

IVF doctors demand details after CooperSurgical lawsuit

Merck, Daiichi strike cancer drug pact worth up to $22 billion

hotspot

entertainment

focus

Supreme Court strikes down use of affirmative action

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Tori Bowie and the unacceptable rates of Black maternal death

ADCs take center stage as promising cancer treatments

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Streamlined flu vaccines recommended by FDA advisory panel

The high cost of giving birth even with insurance

Medicare drug price negotiation continues, as pharma counteroffers

Psychedelics group wrestles with new pharma identity

Longer MASH drug regimen improved liver, Akero study finds

knowledge

Change Healthcare: What is it, why does its cyberattack matter?

Why Talkspace is targeting Medicare, a tricky market

STAT Summit: Ending the crisis of Black deaths in the U.S.

Harvard's David Sinclair gets blowback over aging

FDA clears Verve to begin U.S. study of gene

The problems with dementia villages

explore

knowledge

hotspot

leisure time